Kitov Pharma Ltd. said it entered a settlement agreement regarding three shareholder class action lawsuits filed against the company.

The classes in all the lawsuits, which alleged violations of U.S. federal securities laws, will receive $2 million under the proposed settlement. The Israeli biopharmaceutical company expects its insurers to fund the settlement consideration, plus related expenses.

One lawsuit was filed in the District Court for the Southern District of New York while two were filed in the Superior Court for the State of California.

Under the proposed settlement, which will have no impact on the company's statement of operations, Kitov will not admit any wrongdoing or violation of federal or state securities laws.

The proposal is subject to certain conditions, including court approval.